马萨诸塞州沃特敦 - Kymera Therapeutics (NASDAQ:KYMR)周一宣布,该公司KT-621 BroADen 1b期临床试验在特应性皮炎患者中的数据将在2026年美国皮肤病学会年会上公布,根据一份新闻稿声明。 该公司股价在过去一年飙升157%,市值达到69亿美元。分析师仍持多方态度,最近有六位分析师上调了盈利预期,目标价区间设定在$91至$140之间。 该演讲定于2026年 ...

Kymera Therapeutics (NASDAQ:KYMR)于2026年3月10日(星期二)在Leerink全球医疗保健会议2026上发表演讲,展示了其在靶向蛋白降解领域的进展。首席执行官Nello Mainolfi强调了公司前景看好的临床试验数据和战略计划,同时也承认了未来面临的挑战。此次会议凸显了Kymera在免疫学领域的创新承诺。 关键要点 Kymera的STAT6降解剂KT-621在 ...

We are honored to have our KT-621 BroADen Phase 1b data selected for a late-breaking oral presentation at AAD,” said Jared Gollob, MD, Chief Medical Officer, Kymera Therapeutics. “We look forward to ...

Kymera Therapeutics remains focused on pipeline progression despite a Q4 revenue miss and widening net loss, supported by a robust $1.6 billion cash position. R&D investment surged to $316.6 million ...

CEO Nello Mainolfi had one line on the February 26, 2026 earnings call that deserves attention beyond the headline numbers: his company just put the first IRF5-directed therapy in human history into ...

Reported positive KT-621 (STAT6) Phase 1 healthy volunteer data surpassing Kymera’s target product profile, and further validating its oral, dupilumab-like profile KT-621 BroADen Phase 1b trial in ...

BROADEN2 Phase 2b trial in atopic dermatitis (AD) ongoing, with data expected by mid-2027KT-621 BREADTH Phase 2b trial in asthma ...

Is Drawing Fresh Attention Kymera Therapeutics (KYMR) has been catching more investor attention after a strong share price ...

WATERTOWN, Mass., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines ...

Detailed price information for Travere Therapeutics Inc (TVTX-Q) from The Globe and Mail including charting and trades.